Zobrazeno 1 - 6
of 6
pro vyhledávání: '"David Janhofer"'
Autor:
Sarah Diaddigo, BS, Myles LaValley, BS, Kevin Kuonqui, BS, David Janhofer, MD, Jeffrey Ascherman, MD
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 12, Iss S5, Pp 128-128 (2024)
Externí odkaz:
https://doaj.org/article/dd68d2136fb443ff8ff0bd0ef078c181
Publikováno v:
Plastic and Reconstructive Surgery, Global Open, Vol 11, Iss 10S, Pp 105-105 (2023)
Externí odkaz:
https://doaj.org/article/a10667aa41324a4cb7ec2d1620eef4cc
Autor:
Christine S. Higham, Seth M. Steinberg, Eva Dombi, Arie Perry, Lee J. Helman, Scott M. Schuetze, Joseph A. Ludwig, Arthur Staddon, Mohammed M. Milhem, Daniel Rushing, Robin L. Jones, Michael Livingston, Stewart Goldman, Christopher Moertel, Lars Wagner, David Janhofer, Christina M. Annunziata, Denise Reinke, Lauren Long, David Viskochil, Larry Baker, Brigitte C. Widemann
Publikováno v:
Sarcoma, Vol 2017 (2017)
Background. Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant peripheral nerve sheath tumors (MPNST) has been reported. Methods. We evaluated the objective response (OR) rate of patients with A
Externí odkaz:
https://doaj.org/article/201204feb6c0442c98e1d96badf1ee06
Preclinical assessments of the MEK inhibitor PD-0325901 in a mouse model of neurofibromatosis type 1
Autor:
Richard Scott Dunn, David R. Jones, Mi-Ok Kim, Jianqiang Wu, Eva Dombi, David Janhofer, Tilat A. Rizvi, Edwin Jousma, Andrea R. Masters, Timothy P. Cripe, Nancy Ratner
Publikováno v:
Pediatric Blood & Cancer. 62:1709-1716
Background Neurofibromatosis type 1 (NF1) is a genetic disorder that predisposes affected individuals to formation of benign neurofibromas, peripheral nerve tumors that can be associated with significant morbidity. Loss of the NF1 Ras–GAP protein c
Autor:
David Janhofer, Arie Perry, Brigitte C. Widemann, Mohammed M. Milhem, Lauren Long, Joseph A. Ludwig, Seth M. Steinberg, Denise K. Reinke, Daniel A. Rushing, Larry Baker, Lars M. Wagner, Robin L. Jones, Christine Higham, Stewart Goldman, Arthur P. Staddon, Lee J. Helman, Michael B. Livingston, Scott M. Schuetze, David Viskochil, Christina M. Annunziata, Eva Dombi, Christopher L. Moertel
Publikováno v:
Sarcoma
Sarcoma, vol 2017, iss 15
Sarcoma, Vol 2017 (2017)
Sarcoma, vol 2017, iss 15
Sarcoma, Vol 2017 (2017)
Background. Worse chemotherapy response for neurofibromatosis type 1- (NF1-) associated compared to sporadic malignant peripheral nerve sheath tumors (MPNST) has been reported. Methods. We evaluated the objective response (OR) rate of patients with A
Autor:
Staci Martin Peron, David Janhofer, Brigitte C. Widemann, Jianqiang Wu, Leigh Marcus, Mi-Ok Kim, Edwin Jousma, Andrea Baldwin, Lauren Meyerson Long, Nancy Ratner, Eva Dombi, Richard Scott Dunn, Timothy P. Cripe, Gillespie Andrea, David R. Jones, Patricia Whitcomb, Tilat A. Rizvi
Publikováno v:
Cancer Research. 74:A2-A2
Background: Neurofibromatosis type 1 (NF1) patients are predisposed to develop benign plexiform neurofibromas (PNs) that cause substantial morbidity. Surgery, the only standard treatment, is not feasible for most tumors. The NF1 gene product accelera